What is mProbe?
mProbe Inc. operates at the intersection of advanced biotechnology and data science, specializing in the development of a proprietary technology platform that synthesizes multi-omic diagnostics with sophisticated artificial intelligence. The company is fundamentally transforming the paradigm of disease prediction, prevention, and therapeutic intervention. By focusing on Precision Medicine and Precision Health, mProbe provides actionable insights that enable a more proactive approach to patient care. Its market position is defined by its ability to bridge the gap between complex biological data and clinical utility, making it a critical player in the evolution of predictive healthcare analytics. The firm's commitment to high-fidelity diagnostics positions it as a leader in the shift toward personalized, data-driven medical solutions.
How much funding has mProbe raised?
mProbe has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in mProbe
PPP
Public-Private Partnership
What's next for mProbe?
With the successful completion of this late-stage financing, mProbe is poised to scale its operational capabilities and expand its diagnostic platform's reach. The strategic deployment of this capital will likely focus on enhancing the predictive accuracy of its AI models and broadening the scope of its multi-omic research initiatives. As the company transitions into its next phase of growth, the focus will remain on commercializing its diagnostic tools and forging deeper partnerships within the healthcare ecosystem. By prioritizing the integration of its technology into clinical workflows, mProbe aims to solidify its role as a cornerstone of modern predictive healthcare, ultimately driving better patient outcomes through early detection and personalized treatment strategies.
See full mProbe company page
